Download
40001_2024_Article_1945.pdf 3,32MB
WeightNameValue
1000 Titel
  • Intracerebral haemorrhage in multiple sclerosis: assessing the impact of disease-modifying medications
1000 Autor/in
  1. Ou Yong, Brian M. |
  2. Awuah, Wireko Andrew |
  3. Shah, Muhammad Hamza |
  4. Sanker, Vivek |
  5. Huk, Jonathan Kong Sing |
  6. Venkata, Sujashree Yadala |
  7. Patel, Diti H. |
  8. Tan, Joecelyn Kirani |
  9. Khan, Noor Ayman |
  10. Kulasekaran, Ajitha |
  11. Sarkar, Manali |
  12. Abdul-Rahman, Toufik |
  13. Atallah, Oday |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-06-25
1000 Erschienen in
1000 Quellenangabe
  • 29(1):344
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s40001-024-01945-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197372/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Multiple Sclerosis (MS) is a complex autoimmune disorder that significantly impacts the central nervous system, leading to a range of complications. While intracranial haemorrhage (ICH) is a rare but highly morbid complication, more common CNS complications include progressive multifocal leukoencephalopathy (PML) and other CNS infections. This severe form of stroke, known for its high morbidity and mortality rates, presents a critical challenge in the management of MS. The use of disease-modifying drugs (DMDs) in treating MS introduces a nuanced aspect to patient care, with certain medications like Dimethyl Fumarate and Fingolimod showing potential in reducing the risk of ICH, while others such as Alemtuzumab and Mitoxantrone are associated with an increased risk. Understanding the intricate relationship between these DMDs, the pathophysiological mechanisms of ICH, and the individualised aspects of each patient's condition is paramount. Factors such as genetic predispositions, existing comorbidities, and lifestyle choices play a crucial role in tailoring treatment approaches, emphasising the importance of a personalised, vigilant therapeutic strategy. The necessity for ongoing and detailed research cannot be overstated. It is crucial to explore the long-term effects of DMDs on ICH occurrence and prognosis in MS patients, aiming to refine clinical practices and promote patient-centric, informed therapeutic decisions. This approach ensures that the management of MS is not only comprehensive but also adaptable to the evolving understanding of the disease and its treatments.</jats:p>
1000 Sacherschließung
lokal Mitoxantrone/therapeutic use [MeSH]
lokal Disease-modifying drugs
lokal Blood–brain barrier
lokal Neuroinflammation
lokal Humans [MeSH]
lokal Fingolimod Hydrochloride/therapeutic use [MeSH]
lokal Multiple Sclerosis/drug therapy [MeSH]
lokal Intracerebral haemorrhage
lokal Cerebral Hemorrhage/etiology [MeSH]
lokal Multiple Sclerosis/complications [MeSH]
lokal Dimethyl Fumarate/therapeutic use [MeSH]
lokal Fingolimod Hydrochloride/adverse effects [MeSH]
lokal Dimethyl Fumarate/adverse effects [MeSH]
lokal Multiple sclerosis
lokal Neurological complications
lokal Pharmacotherapy in MS
lokal CNS immunity
lokal Review
lokal Immunosuppressive Agents/therapeutic use [MeSH]
lokal Mitoxantrone/adverse effects [MeSH]
lokal Cerebral Hemorrhage/chemically induced [MeSH]
lokal Immunosuppressive Agents/adverse effects [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/T3UgWW9uZywgQnJpYW4gTS4=|https://frl.publisso.de/adhoc/uri/QXd1YWgsIFdpcmVrbyBBbmRyZXc=|https://frl.publisso.de/adhoc/uri/U2hhaCwgTXVoYW1tYWQgSGFtemE=|https://frl.publisso.de/adhoc/uri/U2Fua2VyLCBWaXZlaw==|https://frl.publisso.de/adhoc/uri/SHVrLCBKb25hdGhhbiBLb25nIFNpbmc=|https://frl.publisso.de/adhoc/uri/VmVua2F0YSwgU3VqYXNocmVlIFlhZGFsYQ==|https://frl.publisso.de/adhoc/uri/UGF0ZWwsIERpdGkgSC4=|https://frl.publisso.de/adhoc/uri/VGFuLCBKb2VjZWx5biBLaXJhbmk=|https://frl.publisso.de/adhoc/uri/S2hhbiwgTm9vciBBeW1hbg==|https://frl.publisso.de/adhoc/uri/S3VsYXNla2FyYW4sIEFqaXRoYQ==|https://frl.publisso.de/adhoc/uri/U2Fya2FyLCBNYW5hbGk=|https://frl.publisso.de/adhoc/uri/QWJkdWwtUmFobWFuLCBUb3VmaWs=|https://frl.publisso.de/adhoc/uri/QXRhbGxhaCwgT2RheQ==
1000 Hinweis
  • DeepGreen-ID: e08d7fdfbe454217b838d30cc19de57e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search) ;
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6521187.rdf
1000 Erstellt am 2025-07-06T06:07:46.712+0200
1000 Erstellt von 322
1000 beschreibt frl:6521187
1000 Zuletzt bearbeitet 2025-08-04T09:07:48.669+0200
1000 Objekt bearb. Mon Aug 04 09:07:48 CEST 2025
1000 Vgl. frl:6521187
1000 Oai Id
  1. oai:frl.publisso.de:frl:6521187 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source